Methylation of PCDH19 predicts poor prognosis of hepatocellular carcinoma

Asia-Pacific Journal of Clinical Oncology
Ting ZhangXiangmei Chen

Abstract

Several members of protocadherins (PCDHs) have been identified as tumor suppressor genes in human carcinogenesis, but little is known about PCDH19. The aim of the present study was to assess the expression and methylation of PCDH19 in hepatocellular carcinoma (HCC). The RNA-seq data from The Cancer Genome Atlas Database were downloaded and used for analyzing PCDH19 expression in HCC patients and normal liver tissues. We collected 63 paired tumor and nontumor liver tissues from hepatitis B virus-related HCC patients. The expression of PCDH19 was detected by real-time quantitative RT-PCR assay. The methylation of PCDH19 gene was analyzed by DNA methylation-sensitive endonuclease digestion and the sequential quantitative PCR. The prognostic value of PCDH19 gene methylation was evaluated by Kaplan-Meier analyses. PCDH19 expression was downregulated in HCC tissues and seven HCC cell lines compared to nontumor tissues. PCHD19 promoter was frequently hypermethylated in three (SMMC7721, Hep3B and SNU387) of seven HCC cell lines and 5-aza-dC treatment could significantly increased the PCDH19 expression in these methylated cells. In addition, HCC tumor tissues exhibited significantly increased PCDH19 hypermethylation both in frequency (3...Continue Reading

References

Aug 16, 2005·Current Opinion in Cell Biology·Dirk JunghansRolf Kemler
Oct 16, 2007·Current Opinion in Cell Biology·Hirofumi Morishita, Takeshi Yagi
Dec 22, 2010·Cell Adhesion & Migration·Soo-Young KimHyun Kim
Dec 21, 2011·The Journal of Cell Biology·Michelle R EmondJames D Jontes
Jan 24, 2012·Human Mutation·Christel Depienne, Eric LeGuern
Aug 31, 2014·Biochemical and Biophysical Research Communications·Pengfei ZhuFengmin Lu
Sep 18, 2014·Genes·Thomas Mikeska, Jeffrey M Craig
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Jan 26, 2016·CA: a Cancer Journal for Clinicians·Wanqing ChenJie He

❮ Previous
Next ❯

Citations

Mar 4, 2020·Expert Review of Gastroenterology & Hepatology·Liping ChenDesong Kong
Jan 31, 2020·BioMed Research International·Hong-Ye JiangWei-Biao Lv
Jul 23, 2020·Frontiers in Molecular Neuroscience·Anna PanchoEve Seuntjens
Sep 9, 2021·Epigenetics : Official Journal of the DNA Methylation Society·Artem V ArtemovEgor B Prokhortchouk

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Nahyeon KangJong Y Park
© 2022 Meta ULC. All rights reserved